Drugs / d-MAPPS
d-MAPPS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06852768 | Jan 2025 → Dec 2026 expected | — | Regenerative Ocular Immunobiologics LLC | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07210619 | — | chronic graft versus host disease | Regenerative Ocular Immunobiologics LLC | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-MAPPS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07210619 ↗ |
| Known as | Sterile Processed Derived Multiple Allogeneic Proteins Paracrine Signaling | “This Expanded Access Policy describes the conditions under which Sterile Processed Derived Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS™ Ophthalmic Solution) may...” NCT07210619 ↗ |
| Route | Other | “Ophthalmic Solution for oGVHD” NCT07210619 ↗ |